Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease

OBJECTIVE: To observe the effect on total liver volume (TLV) on and off therapy in selected symptomatic patients with autosomal dominant polycystic kidney disease (ADPKD) or autosomal dominant polycystic liver disease (PLD) who received octreotide long-acting release (OctLAR) for up to 4 years. PATI...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mayo Clin Proc
Hlavní autoři: Hogan, Marie C., Masyuk, Tetyana, Bergstralh, Eric, Li, Bill, Kremers, Walter K., Vaughan, Lisa E., Ihrke, Angela, Severson, Amanda L., Irazabal, Maria V., Glockner, James, LaRusso, Nicholas F., Torres, Vicente E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4928579/
https://ncbi.nlm.nih.gov/pubmed/26166166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mayocp.2015.05.011
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky